Additionally, as these NK cells are intended to be combined with an anti-CD38 antibody (Daratumumab) to target multiple myeloma, CD38 was deleted from the iPSCs to produce CD38-knockout (KO) iPSC-NK cells that also contain the engineered CD16 and IL15 molecules. This evidence concerns the gene FCGR3A and plasma cell myeloma.